PMLiVE4h
AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn
AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...
PMLiVE4h
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...
PMLiVE3h
What’s next for scientific congress booths: five trends for 2025
In 2025, expect to see a continued emphasis on minimizing the environmental footprint of congress booths without compromising ...
PMLiVE4h
Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
PMLiVE5h
How can we navigate the tension between scientific rigor and emotional resonance in brand storytelling?
In her first Ask Alex article of the year, Scientific Director, Dr Alexandra Loveday explores the ways our expert writers ...
PMLiVE5h
Is modular content the secret to smarter medical communications?
In her latest Ask Alex article, Principal Medical Writer, Dr Alexandra Loveday explores modular content and whether it holds ...
PMLiVE5h
Artificial Intelligence: How to approach the ethical cost of innovation
In a rapidly evolving industry, staying ahead means embracing new tools thoughtfully. We're setting the gold standard by ...